satoreotide tetraxetan

PeptideexperimentalImaging agent

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started May 15, 2019 (NCT03773133)

Timeline

2010s

Jan 1, 2019
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Breast Neoplasms · Phase 1/Phase 2

Mechanism of action

Somatostatin receptorBINDING AGENT
Somatostatin receptor binding agent

Chemistry & pharmacology

Loading structure…

SMILES

C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2ccc(NC(N)=O)cc2)NC(=O)[C@H](Cc2ccc(NC(=O)[C@@H]3CC(=O)NC(=O)N3)cc2)NC(=O)[C@H](NC(=O)[C@H](Cc2ccc(Cl)cc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)CSSC[C@@H](C(=O)N[C@H](Cc2ccc(O)cc2)C(N)=O)NC1=O

Mol. weight: 1689.3 g/mol
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Multi-specific: No
Imaging: 177-Lutetium

Oral

Parenteral

Topical

Sources

ChEMBLCHEMBL4297531 ↗

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT03773133	Phase 1/Phase 2 (Phase 2)	May 15, 2019	Ipsen

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Ipsen	For profit	1	1	1	2019

1 organizations

Page 1 / 1